Recently, it was reported that mesothelioma cells with NF2 and/or LATS2 mutations were more sensitive to fluvastatin compared to those with BAP1 mutations [111], whereas merlin-negative breast cancer cells showed sensitivity to simvastatin [112]. This evidence concerns the gene NF2 and breast cancer.